lansoprazole has been researched along with Peptic Ulcer in 184 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adults with erosive esophagitis were randomized to once-daily vonoprazan, 20 mg, or lansoprazole, 30 mg, for up to 8 weeks." | 9.69 | Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. ( DeVault, K; Hunt, B; Katz, P; Laine, L; Lowe, J; Mitev, S; Spechler, S, 2023) |
| " The aim of this study was to assess the long-term safety of vonoprazan for maintenance treatment of healed erosive oesophagitis versus lansoprazole." | 9.69 | Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. ( Akiyama, J; Aoyama, N; Haruma, K; Kanoo, T; Kinoshita, Y; Kushima, R; Kusumoto, N; Miyata, K; Uemura, N; Yao, T, 2023) |
| "Lansoprazole 30 mg, amoxicillin 1000 mg, and tinidazole 500 mg were given twice daily to 39 peptic ulcer patients (26 duodenal and 13 gastric ulcer, mean age 52." | 9.09 | Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease. ( Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V, 2000) |
| " pylori positive active peptic ulcer disease were randomly assigned to receive lansoprazole 30 mg o." | 9.09 | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. ( Beglinger, C; Drewe, J; Lehmann, FS; Terracciano, L, 2000) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 9.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 9.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 9.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 9.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 9.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| " We conducted a cross-sectional study to compare the prevalence of gastroduodenal ulcers or erosions in patients taking LDA with either 40 mg/day of famotidine or 15 mg/day of lansoprazole for at least three months." | 7.79 | Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2. ( Kadota, J; Murakami, K; Tamura, A, 2013) |
| "A prospective trial was designed to study the effectiveness of the 1-week combination of lansoprazole, clarithromycin and amoxycillin in 102 consecutive patients with active peptic ulcer." | 7.70 | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. ( Ducóns, JA; Ferrero, M; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S, 1999) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 7.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "Based on limited number of published non-inferiority RCTs, our analysis demonstrates that among patients with EE, vonoprazan 20 mg once-daily dosing achieves comparable and in those with severe EE, higher endoscopic healing rates as compared to lansoprazole 30 mg once-daily dosing." | 7.01 | Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials. ( Adler, DG; Bapaye, J; Chandan, OC; Chandan, S; Deliwala, S; Dhindsa, B; Facciorusso, A; Kassab, LL; Mohan, BP; Ramai, D, 2023) |
| "Lansoprazole is a potent antisecretory drug also possessing anti-Helicobacter pylori activity in vitro." | 6.68 | Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. ( Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 6.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| "Adults with erosive esophagitis were randomized to once-daily vonoprazan, 20 mg, or lansoprazole, 30 mg, for up to 8 weeks." | 5.69 | Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. ( DeVault, K; Hunt, B; Katz, P; Laine, L; Lowe, J; Mitev, S; Spechler, S, 2023) |
| " The aim of this study was to assess the long-term safety of vonoprazan for maintenance treatment of healed erosive oesophagitis versus lansoprazole." | 5.69 | Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. ( Akiyama, J; Aoyama, N; Haruma, K; Kanoo, T; Kinoshita, Y; Kushima, R; Kusumoto, N; Miyata, K; Uemura, N; Yao, T, 2023) |
| "This study aimed to explore the non-inferior efficacy and safety of keverprazan to lansoprazole in treating erosive oesophagitis (EO)." | 5.51 | The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study. ( Chen, H; Chen, M; Chen, S; Guo, Q; Li, F; Li, S; Li, X; Liao, A; Liu, C; Liu, D; Miao, X; Wang, Y; Wen, Z; Xia, M; Xiao, Y; Xu, M; Yin, H; Zhang, Y, 2022) |
| "Body weight was measured and blood was collected before and 12 weeks after H." | 5.43 | Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. ( Inoue, H; Ito, M; Kasai, C; Moritani, I; Oya, Y; Shiraki, K; Sugimoto, K; Takase, K; Takei, Y; Tameda, M; Tanaka, J, 2016) |
| "To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use." | 5.27 | Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. ( Ashida, K; Funao, N; Kawai, T; Mizokami, Y; Nishimura, A; Oda, K; Soen, S; Sugano, K, 2018) |
| "Compare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study." | 5.27 | Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. ( Ashida, K; Funao, N; Kawai, T; Matsumoto, Y; Mizokami, Y; Nishimura, A; Oda, K; Sugano, K, 2018) |
| " Group A was the treatment group, receiving lansoprazole OD 30 mg from a nasogastric tube for 14 days, while Group B, the control group, received no proton pump inhibitors or other medications for treating peptic ulcers." | 5.22 | Stress ulcer prophylaxis in patients being weaned from the ventilator in a respiratory care center: A randomized control trial. ( Chung, CS; Hsu, YL; Lee, TH; Lin, CC, 2016) |
| "Helicobacter pylori causes chronic gastritis, gastroduodenal ulcers, and gastric cancer, and has been treated with two antibiotics (amoxicillin and clarithromycin) and proton-pump inhibitors (PPIs)." | 5.22 | The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. ( Chun, J; Kim, BG; Kim, BS; Kim, JS; Kim, JW; Koh, SJ; Lee, KL; Oh, B, 2016) |
| "Patients with high-risk bleeding peptic ulcers after successful endoscopic therapy were randomly assigned as oral lansoprazole or intravenous esomeprazole group." | 5.16 | Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. ( Lin, HJ; Soon, MS; Su, WW; Wu, SS; Yang, CW; Yen, HH, 2012) |
| "To compare the therapeutic effects of proton pump inhibitors (PPI) and histamine 2 receptor antagonists (H2RA) on gastroduodenal ulcers under continuous use of low-dose aspirin." | 5.14 | Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. ( Kato, M; Nema, H, 2010) |
| "We followed up 295 pregnancies exposed to omeprazole [233 in the first trimester (T1)], 62 to lansoprazole (55 in T1) and 53 to pantoprazole (47 in T1), and compared pregnancy outcome to that of 868 European Network of Teratology Information Services controls." | 5.11 | The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. ( Arnon, J; Clementi, M; De Santis, M; Diav-Citrin, O; Malm, H; Ornoy, A; Robert-Gnansia, E; Schaefer, C; Shechtman, S; Valti, E; van Tonningen, MR, 2005) |
| " pylori positive peptic ulcer disease or functional dyspepsia were treated with two-day quadruple therapy (lansoprazole 30 mg twice daily, and colloidal bismuth subcitrate 120 mg, tetracycline 250 mg and metronidazole 250 mg, all eight times a day)." | 5.11 | The influence of pretreatment on cure rates of Helicobacter pylori eradication. ( de Boer, WA; Jansen, JB; Janssen, MJ; Laheij, RJ, 2004) |
| "Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| "The purpose of this study was to compare the efficacy of tinidazole- versus clarithromycin-based triple regimens for eradication of Helicobacter pylori in North Indian patients of peptic ulcer disease, and to correlate the outcome with in vitro antibiotic susceptibility." | 5.11 | Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. ( Ahuja, V; Bal, C; Bhatia, V; Das, B; Sharma, MP, 2004) |
| "To study whether prophylaxis with lansoprazole could prevent relapse of ulcers after eradication of Helicobacter pylori in patients with NSAID-related peptic ulcers." | 5.10 | Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. ( Chan, CK; Chan, OO; Chu, KM; Hu, HC; Hui, WM; Kwok, KF; Lai, KC; Lam, SK; Wong, BC; Wong, WM, 2003) |
| "A randomized, placebo-controlled, treatment trial in Vietnam allocated 296 Helicobacter pylori-infected patients with peptic ulcer of >or= 5 mm to one of three regimens: (i) twice-daily: lansoprazole 30 mg, clarithromycin 250 mg and tinidazole 500 mg; (ii) once-daily: lansoprazole 60 mg, clarithromycin 500 mg and tinidazole 1000 mg; (iii) once-daily: placebo, clarithromycin 500 mg and tinidazole 1000 mg." | 5.10 | Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. ( Björkman, A; Granström, M; Hoang, TT; Phung, DC; Sörberg, M; Wheeldon, TU, 2003) |
| " pylori-infected peptic ulcer patients were randomly treated with either rabeprazole (10 mg b." | 5.10 | Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. ( Habu, Y; Hayakumo, T; Inokuchi, H; Kawabata, H; Kawai, K; Kimoto, K; Kiyota, K; Kobayashi, M; Kutsumi, H; Mizuno, S; Nakajima, M; Oyasu, K; Tomioka, H, 2003) |
| " pylori-positive gastritis or peptic ulcers were randomly assigned to receive 30 mg lansoprazole twice daily (LAC group), 10 mg rabeprazole twice daily (RAC20 group), or 20 mg rabeprazole twice daily (RAC40 group), with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week." | 5.10 | Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. ( Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM, 2003) |
| "Helicobacter pylori-positive patients (224) with peptic ulcer disease or non-ulcer dyspepsia were randomized to receive one of three different omeprazole or lansoprazole-amoxycillin-clarithromycin (PPI/AC) regimens for 7 days: (1) OAC 20 regimen (n = 76), omeprazole (OPZ) 20 mg daily, amoxycillin (AMOX) 500 mg t." | 5.09 | Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. ( Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Shimizu, H; Watanabe, S, 1999) |
| " pylori who had functional dyspepsia were randomly assigned to 7 days of treatment with a lansoprazole-based triple therapy or placebo and then followed for 1 year." | 5.09 | Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. ( Chan, HH; Chen, W; Cheng, JS; Chien, EJ; Hsu, PI; Hsu, PN; Ku, MK; Lai, KH; Lin, CK; Lo, CC; Lo, GH; Peng, NJ; Tseng, HH, 2001) |
| "Lansoprazole 30 mg, amoxicillin 1000 mg, and tinidazole 500 mg were given twice daily to 39 peptic ulcer patients (26 duodenal and 13 gastric ulcer, mean age 52." | 5.09 | Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease. ( Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V, 2000) |
| "We conducted a prospective, uncontrolled study of a consecutive series of 21 peptic ulcer patients with failure of 1-week lansoprazole, amoxicillin, and clarithromycin." | 5.09 | Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. ( Ducóns, JA; Ferrero, M; García Cabezudo, J; Gomollón, F; Guirao, R; Montoro, M; Simón, MA, 1999) |
| " pylori positive active peptic ulcer disease were randomly assigned to receive lansoprazole 30 mg o." | 5.09 | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. ( Beglinger, C; Drewe, J; Lehmann, FS; Terracciano, L, 2000) |
| "Ninety patients with established peptic ulcer and NUD (with previously proven ulcer) were randomly assigned to receive either bismuth-subcitrate, amoxycillin and metrnidazole (BAM) or lansoprasole, clarithromycine and metronidazole (LCM) for 7 days." | 5.09 | The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. ( Avidan, B; Bar-Meir, S; Keller, N; Melzer, E, 2001) |
| "The clinical efficacy of lansoprazole plus amoxicillin treatment in eradicating Helicobacter pylori was examined in peptic ulcer patients." | 5.08 | Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method. ( Ogura, K; Ota, S; Shimada, T; Terano, A, 1995) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 5.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated." | 5.08 | Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995) |
| "In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated." | 5.08 | The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 5.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "Although bismuth was both the first drug shown to alter the natural history of peptic ulcer disease and also a constituent of the first very effective eradication regimens, it has been excluded from the newer regimens, despite its safety and low cost, in favour of two antibiotics." | 5.08 | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. ( Scott, BB, 1998) |
| "We investigated the effects of omeprazole or lansoprazole on peptic ulcer healing, eradication of Helicobacter pylori (Hp) and abdominal symptoms." | 5.08 | Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer. ( Fukuda, Y; Okui, M; Shimoyama, T; Tamura, K; Yamamoto, I, 1995) |
| "A randomized, single-blind study was designed to assess the effect of lansoprazole alone and lansoprazole plus amoxicillin on the healing and eradication rates in Helicobacter pylori-associated peptic ulcer disease." | 5.08 | Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. ( Asaka, M; Kagaya, H; Katagiri, M; Katoh, M; Kudoh, M; Takeda, H, 1995) |
| " pylori-associated gastritis, received seven days of lansoprazole, bismuth, tetracycline and metronidazole after three days of lansoprazole pretreatment." | 5.08 | Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. ( Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB, 1998) |
| " pylori-positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days." | 5.08 | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? ( Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ, 1998) |
| "Patients with active HP infection and peptic ulcer, a history of peptic ulcer, or nonulcer dyspepsia were randomized to either lansoprazole 30 mg b." | 5.08 | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. ( Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM, 1997) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 5.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| " pylori infection, a new one-week triple therapy regimen (lansoprazole or omeprazole + amoxicillin + clarithromycin) has been approved for use in patients with peptic ulcer disease in Japan." | 4.82 | Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. ( Hoshino, Y; Ishii, H; Kurabayashi, K; Masaoka, T; Minegishi, Y; Nomura, S; Suzuki, H; Suzuki, M, 2003) |
| " A daily dose of 30 mg lansoprazole reduced epigastric pain faster than omeprazole 20 mg daily in patients with peptic ulcer disease but healing rates at 4 and 8 weeks were similar with both agents at these dosages." | 4.81 | Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. ( Gremse, DA, 2001) |
| "This meta-analysis reviewed all randomized, controlled clinical trials published as full text articles in English between 1993 and 1996 that reported the efficacy of lansoprazole treatment as monotherapy or in combination with antibiotics in the treatment of peptic ulcer and in eradicating H." | 4.80 | Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. ( Bazzoli, F; Berretti, D; De Luca, L; Fossi, S; Nicolini, G; Pozzato, P; Ricciardiello, L; Zagari, M, 1998) |
| "Aim of this overview was to evaluate the main clinical trials with lansoprazole published from 1997 to 1999 in English-language journals, regarding gastroesophageal reflux disease, peptic ulcer, NSAID-induced ulcer, and ZES." | 4.80 | [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. ( Capurso, L; Dobrilla, G, 2000) |
| "To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e." | 4.79 | Lansoprazole: a proton pump inhibitor. ( Garnett, WR, 1996) |
| " We conducted a cross-sectional study to compare the prevalence of gastroduodenal ulcers or erosions in patients taking LDA with either 40 mg/day of famotidine or 15 mg/day of lansoprazole for at least three months." | 3.79 | Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2. ( Kadota, J; Murakami, K; Tamura, A, 2013) |
| "Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus." | 3.77 | Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. ( Barradell, LB; Faulds, D; McTavish, D, 1992) |
| ", omeprazole, misoprostol, and high-dose famotidine) in the prevention of NSAID-induced gastroduodenal ulcers will also be effective in this setting." | 3.71 | Current approaches to reducing gastrointestinal toxicity of low-dose aspirin. ( Lanas, AI, 2001) |
| "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses." | 3.71 | Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases. ( Athmann, C; Boldt, JH; Brunner, G, 2001) |
| "A prospective trial was designed to study the effectiveness of the 1-week combination of lansoprazole, clarithromycin and amoxycillin in 102 consecutive patients with active peptic ulcer." | 3.70 | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. ( Ducóns, JA; Ferrero, M; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S, 1999) |
| "Thirty-eight clinical strains of Helicobacter pylori were isolated from patients with chronic gastritis and gastroduodenal ulceration, and their susceptibility to macrolide antibiotics (roxithromycin, flurithromycin, azithromycin, erythromycin) in combination with proton-pump inhibitors (lansoprazole and omeprazole) and bismuth subcitrate was assayed." | 3.70 | Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. ( Campa, M; Favini, P; Malizia, T; Marchetti, F; Pizzarelli, G; Senesi, S; Tejada, M, 1998) |
| "We isolated strains of Helicobacter pylori from gastric mucosa of patients with peptic ulcer before and after eradication therapy, and studied their sensitivity to amoxicillin (AMPC) and clarythromycin (CAM)." | 3.70 | [Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy]. ( Honda, T; Matsumoto, T; Mori, K; Nagatomi, Y; Takaba, M; Tsuneoka, H, 1998) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 3.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "To evaluate endogenous and exogenous factors affecting the quality of ulcer healing produced by proton pump inhibitors, gastric acid pH, serum gastrin, and serum pepsinogen (PG) I and II were measured in peptic ulcer patients before and after treatment with lansoprazole 30 mg once daily." | 3.69 | Factors affecting quality of ulcer healing after lansoprazole treatment. ( Hanai, H; Ito, G; Kaneko, E; Nakagawara, M; Nawano, M; Ooi, S; Watanabe, F, 1995) |
| "Based on limited number of published non-inferiority RCTs, our analysis demonstrates that among patients with EE, vonoprazan 20 mg once-daily dosing achieves comparable and in those with severe EE, higher endoscopic healing rates as compared to lansoprazole 30 mg once-daily dosing." | 3.01 | Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials. ( Adler, DG; Bapaye, J; Chandan, OC; Chandan, S; Deliwala, S; Dhindsa, B; Facciorusso, A; Kassab, LL; Mohan, BP; Ramai, D, 2023) |
| " pylori) is complex; full effectiveness is rarely achieved and it has many adverse effects." | 2.78 | Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. ( Barbuti, RC; Bogsan, CS; Chinzon, D; de Oliveira, MN; Eisig, JN; Mattar, R; Moraes-Filho, JP; Navarro-Rodriguez, T; Silva, FM, 2013) |
| "We examined 90 patients with early gastric cancer who had undergone ESD." | 2.78 | Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. ( Asakuma, Y; Kashida, H; Kawasaki, M; Kudo, M; Matsui, S; Sakurai, T; Takayama, M, 2013) |
| "Incidence of gastric cancer in the two groups was determined based on the results of annual endoscopy and questionnaire surveys, as well as Yamagata Prefectural Cancer Registry data, and was compared between the two groups and by results of H pylori therapy." | 2.74 | Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? ( Fukase, K; Kawata, S; Mabe, K; Matsuda, T; Oizumi, H; Shibata, A; Takahashi, M; Takeda, H; Tsukuma, H, 2009) |
| "All peptic ulcers were healed." | 2.69 | Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. ( De Fanis, C; Di Virgilio, M; Pantaleone, U; Pizzicanella, G; Russo, L; Sciampa, G; Silla, M; Spadaccini, A, 1998) |
| " Pre-treatment with a proton pump inhibitor, higher doses or more frequent dosing may be necessary to increase the cure rate of short duration regimens." | 2.69 | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. ( Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M, 1999) |
| " The aim of this study was to determine the optimal dose and duration of lansoprazole (LA) administration in combination with amoxicillin (AMPC) and metronidazole (MNZ)." | 2.69 | Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy. ( Asaka, M; Ishizuka, J; Kagaya, H; Katagiri, M; Kato, M; Komatsu, Y; Kudo, M; Kudo, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H; Toyota, J, 1999) |
| "Lansoprazole is a potent antisecretory drug also possessing anti-Helicobacter pylori activity in vitro." | 2.68 | Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. ( Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB, 1995) |
| "Metronidazole resistance was induced in 8 out of 16 with a sensitive strain." | 2.68 | One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. ( de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ, 1997) |
| "Lansoprazole has superior anti-Helicobacter activity in vitro and possibly also in vivo; therefore we investigated quadruple therapy with lansoprazole." | 2.68 | Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. ( de Boer, WA; Driessen, WM; Lai, JY; Schneeberger, PM; van de Wouw, BA; van Etten, RJ, 1996) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 2.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| "Lansoprazole was found to be effective in patients who exhibited peak 13CO2 values that were at least two-thirds less than the pretreatment values." | 2.68 | 13C-UBT using an infrared spectrometer for detection of Helicobacter pylori and for monitoring the effects of lansoprazole. ( Kajiwara, M; Kokubun, N; Murai, S; Nakagawa, T; Ohara, H; Saito, N; Suzuki, T; Tsujino, D; Yamamoto, M; Yoneshima, M, 1995) |
| "Treatment with misoprostol combined with an H2RA resulted in 60% success for ulcer healing within the next 2 months in nonresponders, without affecting the intraluminal pH measured during treatment with an H2RA alone." | 2.67 | H2-receptor antagonist-refractory ulcer: its pathophysiology and treatment. ( Arakawa, T; Fukuda, T; Higuchi, K; Kobayashi, K; Nakamura, H, 1991) |
| " The results of studies comparing the clinical efficacy of different PPI dosage forms and routes of administration, safety considerations, and cost-effectiveness analyses are among the factors to consider when making formulary decisions for this class of drugs." | 2.43 | Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics. ( Devlin, JW; Olsen, KM; Welage, LS, 2005) |
| "Lansoprazole is a proton pump inhibitor (PPI) which is an effective and well-tolerated treatment option in the management of acid-related disorders." | 2.42 | Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. ( Baldi, F; Malfertheiner, P, 2003) |
| "Studies that appeared to show that GERD could be provoked by antimicrobial therapy of duodenal ulcers also have methodological weaknesses." | 2.41 | Motion--Helicobacter pylori worsens GERD: arguments for the motion. ( O'Morain, CA; Qasim, A, 2002) |
| "Lansoprazole is an inhibitor of gastric acid secretion and also exhibits antibacterial activity against Helicobacter pylori in vitro." | 2.41 | Lansoprazole: an update of its place in the management of acid-related disorders. ( Jarvis, B; Matheson, AJ, 2001) |
| "Eradication rate of Helicobacter pylori in dual therapy (omeprazole/amoxicillin) are reported in the range of 28-91%, side effect such as loose stool and skin reaction are reported 3." | 2.40 | [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy]. ( Iwasaki, A, 1999) |
| " While the short-term risk of complications appears to be minimal, the tolerance of these drugs in chronic use requires careful monitoring because of the potential consequences of prolonged inhibition of acid secretion." | 2.40 | [Proton pump inhibitors in pediatrics]. ( Faure, C; Languepin, J; Pelatan, C, 1999) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion." | 2.40 | Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. ( Langtry, HD; Wilde, MI, 1997) |
| "Lansoprazole has undergone extensive clinical evaluation for the treatment of acid-peptic diseases." | 2.40 | Safety profile of Lansoprazole: the US clinical trial experience. ( Freston, JW; Haber, M; Heller, CA; Jennings, D; Rose, PA, 1999) |
| " The bioavailability of lansoprazole is 85%; that of omeprazole is 54%." | 2.39 | Lansoprazole and omeprazole in the treatment of acid peptic disorders. ( Blum, RA, 1996) |
| " Considerably more work, however, is required to identify the ideal dosage and combination that will give the best eradication rates with the simplest regimen and fewest side effects." | 2.39 | The potential value of lansoprazole in Helicobacter pylori eradication. ( Axon, AT, 1995) |
| " Minor adverse events include headache, diarrhoea, dizziness, pruritus and rash." | 2.39 | Safety of proton pump inhibitors--an overview. ( Arnold, R, 1994) |
| "Omeprazole has been used successfully in the treatment of reflux esophagitis and the Zollinger-Ellison syndrome in the United States over the past year and has received approval recently as first-line therapy for duodenal ulcer disease." | 2.38 | Proton-pump inhibition for acid-related disease. ( Holt, S, 1991) |
| "Body weight was measured and blood was collected before and 12 weeks after H." | 1.43 | Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. ( Inoue, H; Ito, M; Kasai, C; Moritani, I; Oya, Y; Shiraki, K; Sugimoto, K; Takase, K; Takei, Y; Tameda, M; Tanaka, J, 2016) |
| "Omeprazole treatment did not result in mucosal injury or inflammation; however, there were marked shifts in numbers and types of enteric bacteria, including a significant reduction (∼80%) of jejunal Actinobacteria and Bifidobacteria spp." | 1.37 | Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. ( Bercik, P; Bolla, M; Collins, SM; de Palma, G; Denou, E; Jury, J; McKnight, W; Ongini, E; Syer, S; Verdu, E; Vong, L; Wallace, JL, 2011) |
| "Presence of a gastroduodenal ulcer, age, gender and smoking habit did not differ significantly between the eradicated and noneradicated groups." | 1.31 | Failure of Helicobacter pylori eradication: is poor compliance the main cause? ( Baumann, R; Buri, P; Cunningham, M; Dederding, JP; Gallaz, L; Girard, L; Godin, N; Merki, H; Metry, JM; Sitavanc, R; Wermeille, J; Zelger, G, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.54) | 18.7374 |
| 1990's | 92 (50.00) | 18.2507 |
| 2000's | 68 (36.96) | 29.6817 |
| 2010's | 19 (10.33) | 24.3611 |
| 2020's | 4 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, KS | 1 |
| Shah, AK | 1 |
| Bariwal, J | 1 |
| Shelke, SM | 1 |
| Kale, AP | 1 |
| Jagtap, JR | 1 |
| Bhosale, AV | 1 |
| Arikawa, Y | 1 |
| Nishida, H | 1 |
| Kurasawa, O | 1 |
| Hasuoka, A | 1 |
| Hirase, K | 1 |
| Inatomi, N | 3 |
| Hori, Y | 1 |
| Matsukawa, J | 1 |
| Imanishi, A | 1 |
| Kondo, M | 1 |
| Tarui, N | 1 |
| Hamada, T | 1 |
| Takagi, T | 1 |
| Takeuchi, T | 1 |
| Kajino, M | 1 |
| Chen, S | 1 |
| Liu, D | 1 |
| Chen, H | 2 |
| Liao, A | 1 |
| Li, F | 1 |
| Liu, C | 1 |
| Li, X | 1 |
| Li, S | 1 |
| Zhang, Y | 1 |
| Wang, Y | 1 |
| Xia, M | 1 |
| Guo, Q | 1 |
| Miao, X | 1 |
| Wen, Z | 1 |
| Xu, M | 1 |
| Yin, H | 1 |
| Chen, M | 1 |
| Xiao, Y | 1 |
| Laine, L | 1 |
| DeVault, K | 1 |
| Katz, P | 1 |
| Mitev, S | 1 |
| Lowe, J | 1 |
| Hunt, B | 1 |
| Spechler, S | 1 |
| Haruma, K | 2 |
| Kinoshita, Y | 2 |
| Yao, T | 1 |
| Kushima, R | 1 |
| Akiyama, J | 1 |
| Aoyama, N | 3 |
| Kanoo, T | 1 |
| Miyata, K | 1 |
| Kusumoto, N | 1 |
| Uemura, N | 1 |
| Chandan, S | 1 |
| Deliwala, S | 1 |
| Mohan, BP | 1 |
| Ramai, D | 1 |
| Dhindsa, B | 1 |
| Bapaye, J | 1 |
| Kassab, LL | 1 |
| Chandan, OC | 1 |
| Facciorusso, A | 1 |
| Adler, DG | 1 |
| Mizokami, Y | 2 |
| Oda, K | 2 |
| Funao, N | 3 |
| Nishimura, A | 3 |
| Soen, S | 1 |
| Kawai, T | 2 |
| Ashida, K | 3 |
| Sugano, K | 3 |
| Matsumoto, Y | 1 |
| Malfertheiner, P | 2 |
| Navarro-Rodriguez, T | 2 |
| Silva, FM | 2 |
| Barbuti, RC | 2 |
| Mattar, R | 2 |
| Moraes-Filho, JP | 1 |
| de Oliveira, MN | 1 |
| Bogsan, CS | 1 |
| Chinzon, D | 1 |
| Eisig, JN | 2 |
| Tamura, A | 1 |
| Murakami, K | 3 |
| Kadota, J | 1 |
| Sierra, F | 1 |
| Forero, JD | 1 |
| Rey, M | 1 |
| Botero, ML | 1 |
| Cárdenas, A | 1 |
| Liu, MK | 1 |
| Wu, IC | 1 |
| Lu, CY | 1 |
| Kuo, CH | 1 |
| Yu, FJ | 1 |
| Liu, CJ | 1 |
| Hsu, PI | 2 |
| Hsu, WH | 1 |
| Su, YC | 1 |
| Chen, A | 1 |
| Wu, DC | 1 |
| Kuo, FC | 1 |
| Chen, JJ | 1 |
| Onal, IK | 1 |
| Gokcan, H | 1 |
| Benzer, E | 1 |
| Bilir, G | 1 |
| Oztas, E | 1 |
| Takayama, M | 1 |
| Matsui, S | 1 |
| Kawasaki, M | 1 |
| Asakuma, Y | 1 |
| Sakurai, T | 1 |
| Kashida, H | 1 |
| Kudo, M | 2 |
| Lin, CC | 1 |
| Hsu, YL | 1 |
| Chung, CS | 1 |
| Lee, TH | 1 |
| Queiroz, EC | 1 |
| Iriya, K | 1 |
| Lee, JH | 1 |
| Oh, B | 1 |
| Kim, BS | 1 |
| Kim, JW | 2 |
| Kim, JS | 1 |
| Koh, SJ | 1 |
| Kim, BG | 1 |
| Lee, KL | 1 |
| Chun, J | 1 |
| Sakurai, Y | 1 |
| Shiino, M | 1 |
| Asaka, M | 7 |
| Chen, Q | 1 |
| Zhang, W | 1 |
| Fu, Q | 1 |
| Liang, X | 1 |
| Liu, W | 1 |
| Xiao, S | 1 |
| Lu, H | 1 |
| Kasai, C | 1 |
| Sugimoto, K | 1 |
| Moritani, I | 1 |
| Tanaka, J | 1 |
| Oya, Y | 1 |
| Inoue, H | 1 |
| Tameda, M | 1 |
| Shiraki, K | 1 |
| Ito, M | 1 |
| Takei, Y | 1 |
| Takase, K | 1 |
| Hong, EJ | 1 |
| Park, DI | 1 |
| Oh, SJ | 1 |
| Song, MJ | 1 |
| Choi, WH | 1 |
| Hong, CH | 1 |
| Park, JH | 1 |
| Kim, HJ | 1 |
| Cho, YK | 1 |
| Shon, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Mabe, K | 1 |
| Takahashi, M | 2 |
| Oizumi, H | 1 |
| Tsukuma, H | 1 |
| Shibata, A | 1 |
| Fukase, K | 1 |
| Matsuda, T | 1 |
| Takeda, H | 3 |
| Kawata, S | 1 |
| Nema, H | 1 |
| Kato, M | 5 |
| Wallace, JL | 1 |
| Syer, S | 1 |
| Denou, E | 1 |
| de Palma, G | 1 |
| Vong, L | 1 |
| McKnight, W | 1 |
| Jury, J | 1 |
| Bolla, M | 1 |
| Bercik, P | 1 |
| Collins, SM | 1 |
| Verdu, E | 1 |
| Ongini, E | 1 |
| Yen, HH | 1 |
| Yang, CW | 1 |
| Su, WW | 1 |
| Soon, MS | 1 |
| Wu, SS | 1 |
| Lin, HJ | 1 |
| Inaba, T | 1 |
| Mizuno, M | 2 |
| Kawai, K | 2 |
| Yokota, K | 1 |
| Oguma, K | 1 |
| Miyoshi, M | 1 |
| Take, S | 1 |
| Okada, H | 1 |
| Tsuji, T | 1 |
| Vanderhoff, BT | 1 |
| Tahboub, RM | 1 |
| Fujishiro, H | 1 |
| Amano, Y | 1 |
| Adachi, K | 1 |
| Campbell, DR | 1 |
| Haber, MM | 1 |
| Sheldon, E | 1 |
| Collis, C | 1 |
| Lukasik, N | 1 |
| Huang, B | 1 |
| Goldstein, JL | 1 |
| O'Morain, CA | 1 |
| Qasim, A | 1 |
| Maiden, LP | 1 |
| Harris, AW | 1 |
| Kim, JI | 1 |
| Park, SH | 1 |
| Kim, JK | 1 |
| Chung, IS | 1 |
| Chung, KW | 1 |
| Sun, HS | 1 |
| Kawabata, H | 1 |
| Habu, Y | 1 |
| Tomioka, H | 1 |
| Kutsumi, H | 1 |
| Kobayashi, M | 1 |
| Oyasu, K | 1 |
| Hayakumo, T | 1 |
| Mizuno, S | 1 |
| Kiyota, K | 1 |
| Nakajima, M | 1 |
| Kimoto, K | 1 |
| Inokuchi, H | 1 |
| Miki, I | 1 |
| Sakai, T | 1 |
| Shirasaka, D | 2 |
| Wambura, CM | 1 |
| Maekawa, S | 1 |
| Kuroda, K | 1 |
| Tamura, T | 1 |
| Kita, T | 2 |
| Sakaeda, T | 1 |
| Okumura, K | 2 |
| Kasuga, M | 1 |
| Baldi, F | 1 |
| Sugiyama, T | 3 |
| Satoh, K | 3 |
| Kuwayama, H | 4 |
| Fukuda, Y | 4 |
| Fujioka, T | 3 |
| Takemoto, T | 2 |
| Kimura, K | 4 |
| Shimoyama, T | 4 |
| Shimizu, K | 2 |
| Kobayashi, S | 2 |
| Wheeldon, TU | 2 |
| Hoang, TT | 2 |
| Phung, DC | 1 |
| Björkman, A | 1 |
| Granström, M | 2 |
| Sörberg, M | 2 |
| Suzuki, H | 1 |
| Masaoka, T | 1 |
| Nomura, S | 1 |
| Hoshino, Y | 1 |
| Kurabayashi, K | 1 |
| Minegishi, Y | 1 |
| Suzuki, M | 1 |
| Ishii, H | 1 |
| Lai, KC | 3 |
| Lam, SK | 3 |
| Chu, KM | 3 |
| Hui, WM | 3 |
| Kwok, KF | 1 |
| Wong, BC | 3 |
| Hu, HC | 1 |
| Wong, WM | 3 |
| Chan, OO | 1 |
| Chan, CK | 1 |
| Takahashi, S | 2 |
| Furuta, T | 2 |
| Shirai, N | 1 |
| Xiao, F | 1 |
| El-Omar, EM | 1 |
| Rabkin, CS | 1 |
| Sugimura, H | 1 |
| Ishizaki, T | 1 |
| Ohashi, K | 1 |
| Bhatia, V | 1 |
| Ahuja, V | 1 |
| Das, B | 1 |
| Bal, C | 1 |
| Sharma, MP | 1 |
| Phuncarg, DC | 1 |
| Nilsson, LE | 1 |
| Kondo, Y | 1 |
| Joh, T | 1 |
| Sasaki, M | 1 |
| Oshima, T | 1 |
| Itoh, K | 1 |
| Tanida, S | 1 |
| Kataoka, H | 1 |
| Ohara, H | 2 |
| Nomura, T | 1 |
| Itoh, M | 1 |
| Janssen, MJ | 1 |
| Laheij, RJ | 1 |
| Jansen, JB | 1 |
| de Boer, WA | 5 |
| Pilotto, A | 2 |
| Franceschi, M | 2 |
| Longoa, MG | 1 |
| Scarcelli, C | 1 |
| Orsitto, G | 1 |
| Perri, FC | 1 |
| D'Ambrosio, LP | 1 |
| Leandro, G | 2 |
| Asfeldt, AM | 1 |
| Løchen, ML | 1 |
| Straume, B | 1 |
| Steigen, SE | 1 |
| Florholmen, J | 1 |
| Goll, R | 1 |
| Nestegard, O | 1 |
| Paulssen, EJ | 1 |
| Diav-Citrin, O | 1 |
| Arnon, J | 1 |
| Shechtman, S | 1 |
| Schaefer, C | 1 |
| van Tonningen, MR | 1 |
| Clementi, M | 1 |
| De Santis, M | 1 |
| Robert-Gnansia, E | 1 |
| Valti, E | 1 |
| Malm, H | 1 |
| Ornoy, A | 1 |
| Feng, LY | 1 |
| Yao, XX | 1 |
| Jiang, SL | 1 |
| Miyake, K | 1 |
| Ueki, N | 1 |
| Suzuki, K | 2 |
| Shinji, Y | 1 |
| Kusunoki, M | 1 |
| Hiratsuka, T | 1 |
| Nishigaki, H | 1 |
| Tatsuguchi, A | 1 |
| Futagami, S | 1 |
| Wada, K | 1 |
| Tsukui, T | 1 |
| Nakajima, A | 1 |
| Yoshino, S | 1 |
| Sakamoto, C | 1 |
| Magalhães, AF | 1 |
| Carvalhaes, A | 1 |
| Natan-Eisig, J | 1 |
| Paraíso-Ferraz, JG | 1 |
| Trevisan, M | 1 |
| Zaterkaad, S | 1 |
| Devlin, JW | 1 |
| Welage, LS | 1 |
| Olsen, KM | 1 |
| Hu, WH | 2 |
| Chan, AO | 2 |
| Wong, J | 2 |
| Calvet, X | 1 |
| Gomollón, F | 3 |
| Schaeverbeke, T | 1 |
| Broutet, N | 1 |
| Zerbib, F | 1 |
| Combe, B | 1 |
| Bertin, P | 1 |
| Lamouliatte, H | 1 |
| Perié, F | 1 |
| Joubert-Collin, M | 1 |
| Mégraud, F | 1 |
| Chung, SJ | 1 |
| Lee, DH | 1 |
| Kim, N | 1 |
| Jung, SH | 1 |
| Hwang, JH | 1 |
| Park, YS | 1 |
| Lee, KH | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Okimoto, T | 1 |
| Kodama, M | 1 |
| Sato, R | 1 |
| Watanabe, K | 1 |
| Dítĕ, P | 1 |
| Prásek, J | 1 |
| Jensen, RT | 1 |
| Fraker, DL | 1 |
| Shimada, T | 1 |
| Ogura, K | 1 |
| Ota, S | 1 |
| Terano, A | 1 |
| Katoh, M | 1 |
| Kudoh, M | 1 |
| Kagaya, H | 2 |
| Katagiri, M | 2 |
| Suzuki, T | 1 |
| Nakagawa, T | 1 |
| Yoneshima, M | 1 |
| Yamamoto, M | 1 |
| Tsujino, D | 1 |
| Murai, S | 1 |
| Saito, N | 1 |
| Kokubun, N | 1 |
| Kajiwara, M | 1 |
| Futami, H | 1 |
| Arai, H | 1 |
| Hanai, H | 2 |
| Kaneko, E | 2 |
| Fujino, MA | 1 |
| Morozumi, A | 1 |
| Kobayashi, K | 2 |
| Ueda, F | 1 |
| Suzuki, Y | 1 |
| Uchida, N | 1 |
| Tachikawa, H | 1 |
| Sano, S | 1 |
| Ohtsuka, H | 1 |
| Yamamoto, Y | 2 |
| Asaki, S | 1 |
| Sato, A | 1 |
| Sakurada, H | 1 |
| Takeda, T | 1 |
| Hongo, M | 1 |
| Toyota, T | 1 |
| Sakaguchi, M | 1 |
| Tanaka, M | 1 |
| Takiuchi, H | 1 |
| Egashira, Y | 1 |
| Katsu, K | 1 |
| Ito, G | 1 |
| Nakagawara, M | 1 |
| Watanabe, F | 1 |
| Ooi, S | 1 |
| Nawano, M | 1 |
| Hoshino, E | 1 |
| Umeda, N | 1 |
| Sano, J | 1 |
| Miki, K | 1 |
| Yahagi, N | 1 |
| Oka, M | 1 |
| Kimura, M | 1 |
| Miyashita, H | 1 |
| Mine, T | 1 |
| Yasuda, H | 1 |
| Akimoto, K | 1 |
| Katoaka, A | 1 |
| Mashima, H | 1 |
| Tajima, A | 1 |
| Fukujin, H | 1 |
| Tsuchida, T | 1 |
| Takano, T | 1 |
| Nagasawa, J | 1 |
| Ohashi, T | 1 |
| Sakata, J | 1 |
| Haraguchi, Y | 1 |
| Eto, T | 1 |
| Murakami, M | 3 |
| Saita, H | 2 |
| Takahashi, Y | 2 |
| Kusaka, S | 1 |
| Asagoe, K | 1 |
| Dekigai, H | 1 |
| Matsumoto, M | 1 |
| Seki, M | 1 |
| Maeda, S | 1 |
| Ogoshi, K | 1 |
| Kato, T | 2 |
| Sakagawa, T | 1 |
| Sezai, S | 1 |
| Sakurabayashi, S | 1 |
| Hirano, M | 1 |
| Oka, H | 1 |
| Yamamoto, I | 1 |
| Okui, M | 1 |
| Tamura, K | 2 |
| Axon, AT | 1 |
| Scheen, AJ | 1 |
| Harada, T | 1 |
| Creutzfeldt, W | 2 |
| Arnold, R | 3 |
| Brunner, G | 2 |
| Hennig, U | 1 |
| Fuchs, W | 3 |
| Takimoto, T | 1 |
| Taniguchi, Y | 1 |
| Saifuku, K | 1 |
| Kihira, K | 2 |
| Yoshida, Y | 3 |
| Ido, K | 1 |
| Hatlebakk, JG | 1 |
| Nesje, LB | 1 |
| Hausken, T | 1 |
| Bang, CJ | 1 |
| Berstad, A | 1 |
| Blum, RA | 2 |
| Meyer, UA | 1 |
| Hopefl, A | 1 |
| Tonokatsu, Y | 1 |
| Tsujiai, T | 1 |
| Leonhardt, U | 1 |
| Ritzel, U | 1 |
| Ramadori, G | 1 |
| Garnett, WR | 1 |
| Tamura, H | 1 |
| Tokushima, H | 1 |
| Murakawa, M | 1 |
| Matsumura, O | 1 |
| Itoyama, S | 1 |
| Sekine, S | 1 |
| Hirose, H | 1 |
| Mitarai, T | 1 |
| Isoda, K | 1 |
| van Etten, RJ | 2 |
| Schade, RW | 1 |
| Ouwehand, ME | 1 |
| Schneeberger, PM | 3 |
| van Unnik, AJ | 1 |
| Tytgat, GN | 1 |
| Müller, P | 2 |
| Simon, B | 2 |
| Bateman, DN | 1 |
| Langtry, HD | 1 |
| Wilde, MI | 1 |
| Matsukura, N | 1 |
| Chey, WD | 1 |
| Fisher, L | 1 |
| Elta, GH | 1 |
| Barnett, JL | 1 |
| Nostrant, T | 1 |
| DelValle, J | 1 |
| Hasler, WL | 1 |
| Scheiman, JM | 1 |
| Zuberi, BF | 1 |
| Lal, S | 1 |
| Sheikh, RM | 1 |
| Lai, JY | 2 |
| van de Wouw, BA | 1 |
| Driessen, WM | 1 |
| Pipkin, GA | 1 |
| Dixon, JS | 1 |
| Williamson, R | 1 |
| Wood, JR | 1 |
| Franko, TG | 1 |
| Richter, JE | 1 |
| Hahm, KB | 1 |
| Lee, KJ | 1 |
| Kim, YS | 1 |
| Kim, JH | 1 |
| Cho, SW | 1 |
| Yim, H | 1 |
| Joo, HJ | 1 |
| Haga, Y | 1 |
| Nakatsura, T | 1 |
| Shibata, Y | 1 |
| Sameshima, H | 1 |
| Nakamura, Y | 1 |
| Tanimura, M | 1 |
| Ogawa, M | 1 |
| Matsukawa, Y | 1 |
| Nishinarita, S | 1 |
| Kaneko, M | 1 |
| Takei, M | 1 |
| Horie, T | 1 |
| Kawamura, F | 1 |
| Arakawa, Y | 1 |
| Kurosaka, H | 1 |
| Perng, CL | 1 |
| Kim, JG | 1 |
| El-Zimaity, HM | 1 |
| Osato, MS | 1 |
| Graham, DY | 1 |
| Lindsetmo, RO | 1 |
| Johnsen, R | 1 |
| Revhaug, A | 1 |
| O'Connor, HJ | 1 |
| McLoughlin, R | 1 |
| Kelly, S | 1 |
| Laundon, J | 1 |
| Cunnane, K | 1 |
| Scott, BB | 1 |
| Malizia, T | 1 |
| Tejada, M | 1 |
| Marchetti, F | 1 |
| Favini, P | 1 |
| Pizzarelli, G | 1 |
| Campa, M | 1 |
| Senesi, S | 1 |
| Tsuneoka, H | 1 |
| Takaba, M | 1 |
| Nagatomi, Y | 1 |
| Mori, K | 1 |
| Matsumoto, T | 1 |
| Honda, T | 1 |
| de Boer, SY | 1 |
| Siem, TH | 1 |
| Treiber, G | 2 |
| Lambert, JR | 1 |
| Hunt, RH | 2 |
| Kidd, SL | 1 |
| Shi, H | 1 |
| Jennings, DE | 1 |
| Greski-Rose, PA | 1 |
| Hashimoto, Y | 1 |
| Sou, Y | 1 |
| Kaitani, K | 1 |
| Nishio, K | 1 |
| Korman, MG | 1 |
| Bolin, TD | 1 |
| Nicholson, FB | 1 |
| Engelman, JL | 1 |
| Bazzoli, F | 1 |
| Pozzato, P | 1 |
| Zagari, M | 1 |
| Fossi, S | 1 |
| Ricciardiello, L | 1 |
| Nicolini, G | 1 |
| Berretti, D | 1 |
| De Luca, L | 1 |
| Louw, JA | 1 |
| Van Rensburg, CJ | 1 |
| Moola, S | 1 |
| Kotze, D | 1 |
| Marks, IN | 1 |
| Baczek, J | 1 |
| Laskowiec, G | 1 |
| Spadaccini, A | 1 |
| De Fanis, C | 1 |
| Sciampa, G | 1 |
| Russo, L | 1 |
| Silla, M | 1 |
| Pantaleone, U | 1 |
| Di Virgilio, M | 1 |
| Pizzicanella, G | 1 |
| Howden, CW | 2 |
| Freedman, MD | 1 |
| Iwasaki, A | 1 |
| Shirai, T | 1 |
| Kurumada, T | 1 |
| Kouda, K | 1 |
| Watanabe, S | 2 |
| Tada, U | 1 |
| Wada, T | 1 |
| Takagi, A | 1 |
| Harasawa, S | 1 |
| Miwa, T | 1 |
| Nakagawa, M | 1 |
| Ooishi, M | 1 |
| Yoda, Y | 1 |
| Kawamura, N | 1 |
| Ooizumi, H | 1 |
| Saitou, M | 1 |
| Nakagawa, S | 1 |
| Sato, K | 3 |
| Kumakura, Y | 1 |
| Freston, JW | 1 |
| Rose, PA | 1 |
| Heller, CA | 1 |
| Haber, M | 1 |
| Jennings, D | 1 |
| Miwa, H | 2 |
| Nagahara, A | 2 |
| Ohkura, R | 2 |
| Murai, T | 1 |
| Shimizu, H | 1 |
| Sato, N | 2 |
| Bozzola, L | 1 |
| Fortunato, A | 1 |
| Rassu, M | 1 |
| Meli, S | 1 |
| Soffiati, G | 1 |
| Scagnelli, M | 1 |
| Di Mario, F | 1 |
| Valerio, G | 1 |
| Ducóns, JA | 2 |
| Santolaria, S | 1 |
| Guirao, R | 2 |
| Ferrero, M | 2 |
| Montoro, M | 2 |
| Sieg, A | 1 |
| Sellinger, M | 1 |
| Schlauch, D | 1 |
| Hörner, M | 1 |
| Grimley, CE | 1 |
| Penny, A | 1 |
| O'sullivan, M | 1 |
| Shebani, M | 1 |
| Lismore, JR | 1 |
| Cross, R | 1 |
| Illing, RC | 1 |
| Loft, DE | 1 |
| Nwokolo, CU | 1 |
| Faure, C | 1 |
| Pelatan, C | 1 |
| Languepin, J | 1 |
| de Grauw, WJ | 1 |
| García Cabezudo, J | 1 |
| Simón, MA | 1 |
| Nishikawa, K | 1 |
| Ishizuka, J | 1 |
| Kudo, T | 1 |
| Komatsu, Y | 1 |
| Sukegawa, M | 1 |
| Toyota, J | 1 |
| van Doorn, LJ | 2 |
| Nouhan, N | 1 |
| Plaisier, AP | 1 |
| Quint, WG | 1 |
| Lehmann, FS | 1 |
| Drewe, J | 1 |
| Terracciano, L | 1 |
| Beglinger, C | 1 |
| Dobrilla, G | 1 |
| Capurso, L | 1 |
| Azuma, T | 2 |
| Ito, S | 2 |
| Suto, H | 1 |
| Ito, Y | 1 |
| Miyaji, H | 1 |
| Yamazaki, Y | 2 |
| Kuriyama, M | 1 |
| Kullavanijaya, P | 1 |
| Gonlachanvit, S | 1 |
| Mahachai, V | 1 |
| Kladchareon, N | 1 |
| Amidon, PB | 1 |
| Jankovich, R | 1 |
| Stoukides, CA | 1 |
| Kaul, AF | 1 |
| Giannini, E | 1 |
| Romagnoli, P | 1 |
| Fasoli, A | 1 |
| Chiarbonello, B | 1 |
| Malfatti, F | 1 |
| Botta, F | 1 |
| Risso, D | 1 |
| Lantieri, PB | 1 |
| Savarino, V | 1 |
| Testa, R | 1 |
| Lai, KH | 1 |
| Tseng, HH | 1 |
| Lo, GH | 1 |
| Lo, CC | 1 |
| Lin, CK | 1 |
| Cheng, JS | 1 |
| Chan, HH | 1 |
| Ku, MK | 1 |
| Peng, NJ | 1 |
| Chien, EJ | 1 |
| Chen, W | 1 |
| Hsu, PN | 1 |
| Lanas, AI | 1 |
| Endo, H | 1 |
| Yoshida, H | 1 |
| Ohmi, N | 1 |
| Higuchi, S | 1 |
| Avidan, B | 1 |
| Melzer, E | 1 |
| Keller, N | 1 |
| Bar-Meir, S | 1 |
| Hiruma-Lima, CA | 1 |
| Gracioso, JS | 1 |
| Toma, W | 1 |
| Almeida, AB | 1 |
| Paula, AC | 1 |
| Brasil, DS | 1 |
| Muller, AH | 1 |
| Souza Brito, AR | 1 |
| Athmann, C | 1 |
| Boldt, JH | 1 |
| Yamada, T | 1 |
| Hojo, M | 1 |
| Grigor'ev, PIa | 1 |
| Iakovenko, EP | 1 |
| Talanova, EV | 1 |
| Matheson, AJ | 1 |
| Jarvis, B | 1 |
| Naesdal, J | 1 |
| Wilson, I | 1 |
| Wittig, J | 1 |
| Ammon, S | 1 |
| Walker, S | 1 |
| Klotz, U | 1 |
| Gremse, DA | 1 |
| Barth, J | 1 |
| Hahne, W | 1 |
| Nakamura, T | 1 |
| Kamada, T | 1 |
| Kusunoki, H | 1 |
| Miyatani, H | 1 |
| Tokuyama, T | 1 |
| Hirakawa, R | 1 |
| Sawada, A | 1 |
| Watanabe, T | 1 |
| Chiba, T | 1 |
| Tanaka, A | 1 |
| Suga, M | 1 |
| Takata, H | 1 |
| Ohara, T | 1 |
| Koizumi, K | 1 |
| Kiriyama, Y | 1 |
| Wermeille, J | 1 |
| Cunningham, M | 1 |
| Dederding, JP | 1 |
| Girard, L | 1 |
| Baumann, R | 1 |
| Zelger, G | 1 |
| Buri, P | 1 |
| Metry, JM | 1 |
| Sitavanc, R | 1 |
| Gallaz, L | 1 |
| Merki, H | 1 |
| Godin, N | 1 |
| Lau, GK | 1 |
| Yuen, MF | 1 |
| Lai, CL | 1 |
| Yanai, H | 1 |
| Tada, M | 1 |
| Okita, K | 1 |
| Sato, Y | 1 |
| Miyazaki, T | 1 |
| Yukawa, K | 1 |
| Yukawa, E | 1 |
| Barradell, LB | 1 |
| Faulds, D | 1 |
| McTavish, D | 1 |
| Holt, S | 1 |
| Arakawa, T | 1 |
| Higuchi, K | 1 |
| Fukuda, T | 1 |
| Nakamura, H | 1 |
| Nakahara, A | 1 |
| Kashimura, H | 1 |
| Fukutomi, H | 1 |
| Nagaya, H | 2 |
| Takami, K | 1 |
| Shino, A | 1 |
| Satoh, H | 2 |
| Inada, I | 1 |
| Nohara, A | 1 |
| Nakamura, N | 1 |
| Maki, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Two Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients With Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan[NCT04124926] | Phase 3 | 1,027 participants (Actual) | Interventional | 2019-10-28 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Lo[NCT01452750] | Phase 3 | 642 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-[NCT01456260] | Phase 3 | 406 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Lo[NCT01452763] | Phase 3 | 621 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-[NCT01456247] | Phase 3 | 439 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Comparison of Vonoprazan and Amoxicillin Dual Therapy With Standard Triple Therapy With Proton Pump Inhibitor for Helicobacter Pylori Eradication; a Randomized Control Trial[NCT04901663] | Phase 4 | 179 participants (Actual) | Interventional | 2021-06-21 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole[NCT01505127] | Phase 3 | 650 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Oral vs Intravenous Proton Pump Inhibitor（PPI） in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial[NCT01123031] | Phase 4 | 0 participants (Actual) | Interventional | 2010-04-30 | Withdrawn (stopped due to The study was terminated and the PI has left the institution.) | ||
| Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics: Multicentre, Randomized, and Controlled Trials[NCT05861687] | Phase 2/Phase 3 | 51 participants (Actual) | Interventional | 2021-08-01 | Completed | ||
| Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976] | Phase 4 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase. (NCT04124926)
Timeframe: Day 1 to Week 8
| Intervention | percentage of days (Mean) |
|---|---|
| Healing Phase: Vonoprazan 20 mg | 66.8 |
| Healing Phase: Lansoprazole 30 mg | 64.1 |
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. (NCT04124926)
Timeframe: Week 2
| Intervention | percentage of participants (Number) |
|---|---|
| Healing Phase: Vonoprazan 20 mg | 74.3 |
| Healing Phase: Lansoprazole 30 mg | 68.2 |
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. (NCT04124926)
Timeframe: Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Healing Phase: Vonoprazan 20 mg | 92.9 |
| Healing Phase: Lansoprazole 30 mg | 84.6 |
"A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.~LA Classification of Esophagitis Grading Scale:~Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference.~Grade D: One or more mucosal breaks, which involves at least 75% of the circumference." (NCT04124926)
Timeframe: Week 2
| Intervention | percentage of participants (Number) |
|---|---|
| Healing Phase: Vonoprazan 20 mg | 70.2 |
| Healing Phase: Lansoprazole 30 mg | 52.6 |
"A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.~LA Classification of Esophagitis Grading Scale:~Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference.~Grade D: One or more mucosal breaks, which involves at least 75% of the circumference." (NCT04124926)
Timeframe: Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Healing Phase: Vonoprazan 20 mg | 91.7 |
| Healing Phase: Lansoprazole 30 mg | 72.0 |
Sustained resolution was defined as at least 7 consecutive days with no daytime or night time heartburn as assessed by the daily diary. A participant was considered to have sustained resolution of heartburn by Day 3 if the first day of the 7 consecutive days without symptoms was on Days 1, 2, or 3. (NCT04124926)
Timeframe: Day 1 to maximum of Day 10 (inclusive of 7 day heartburn assessment)
| Intervention | percentage of participants (Number) |
|---|---|
| Healing Phase: Vonoprazan 20 mg | 34.4 |
| Healing Phase: Lansoprazole 30 mg | 32.2 |
A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase. (NCT04124926)
Timeframe: Day 1 to Week 24
| Intervention | percentage of days (Mean) |
|---|---|
| Maintenance Phase: Vonoprazan 10 mg | 80.9 |
| Maintenance Phase: Vonoprazan 20 mg | 80.6 |
| Maintenance Phase: Lansoprazole 15 mg | 78.6 |
A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. (NCT04124926)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Maintenance Phase: Vonoprazan 10 mg | 79.2 |
| Maintenance Phase: Vonoprazan 20 mg | 80.7 |
| Maintenance Phase: Lansoprazole 15 mg | 72.0 |
"A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.~LA Classification of Esophagitis Grading Scale:~Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference.~Grade D: One or more mucosal breaks, which involves at least 75% of the circumference." (NCT04124926)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Maintenance Phase: Vonoprazan 10 mg | 74.7 |
| Maintenance Phase: Vonoprazan 20 mg | 77.2 |
| Maintenance Phase: Lansoprazole 15 mg | 61.5 |
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 6.45 | 6.38 | 4.54 | 4.14 | 2.62 |
| Placebo | 7.10 | 6.57 | 5.53 | 5.07 | 6.21 |
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Prenaprosyn Baseline | Postnaprosyn baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 18.85 | 18.00 | 11.28 | 10.61 | 8.38 |
| Placebo | 20.26 | 16.78 | 12.85 | 12.74 | 13.75 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 38.28 | 22.36 | 17.50 | 15.28 |
| Placebo | 34.11 | 27.00 | 23.10 | 19.91 |
Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4
| Intervention | Minutes (Mean) | |||
|---|---|---|---|---|
| postnaprosyn baseline | week 1 | week 2 | Week 4 | |
| Eszopiclone | 316.96 | 403.47 | 421.97 | 411.97 |
| Placebo | 380.45 | 375.56 | 382.11 | 388.96 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | awakenings (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 2.29 | 1.31 | 1.35 | 1.33 |
| Placebo | 2.08 | 1.98 | 2.13 | 2.34 |
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.02 | 3.54 | 3.30 | 3.08 |
| Placebo | 3.90 | 3.82 | 4.01 | 3.80 |
"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 12.27 | 9.97 | 9.10 | 7.63 | 6.59 |
| Placebo | 11.33 | 10.30 | 9.05 | 9.32 | 7.94 |
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.52 | 5.99 | 6.18 | 6.38 |
| Placebo | 4.44 | 4.90 | 5.33 | 5.29 |
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 48.51 | 40.72 | 34.70 | 31.69 |
| Placebo | 53.79 | 51.99 | 51.25 | 51.60 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 91.51 | 49.34 | 37.07 | 36.74 |
| Placebo | 81.43 | 76.71 | 81.32 | 76.18 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
43 reviews available for lansoprazole and Peptic Ulcer
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
Topics: Esophagitis; Humans; Lansoprazole; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Randomized Contro | 2023 |
[Several points that should be noticed during PPI treatment for peptic ulcers in elderly patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Drug Interactions; Helicobacter In | 2002 |
Motion--Helicobacter pylori worsens GERD: arguments for the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials a | 2002 |
[Guidelines in the management of Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gas | 2003 |
Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Biological Availab | 2003 |
Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Apoptosis; Chemistry, Clinical; Clari | 2003 |
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointes | 2003 |
Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Capsules; Humans; Lansopr | 2005 |
What is potent acid inhibition, and how can it be achieved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2005 |
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 1995 |
The potential value of lansoprazole in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter | 1995 |
[New therapy of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alprostadil; Anti-Ulcer Agents; Histamine H2 Antagonists; H | 1995 |
[Are proton pump inhibitors safe?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Carcinogenicity | 1994 |
Safety of proton pump inhibitors--an overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cytochrome P-450 Enzyme System; Di | 1994 |
Lansoprazole and omeprazole in the treatment of acid peptic disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Interacti | 1996 |
Lansoprazole: a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Esophagitis; Humans; | 1996 |
[Helicobacter pylori eradication: modified triple therapy with lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter | 1996 |
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastrointestinal Diseases; | 1997 |
Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; C | 1997 |
Proton-pump inhibitors for gastric acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastric Acid; Helicobacter | 1998 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer | 1998 |
Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1998 |
[Lansoprazol ++ : a new proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Lansoprazole; Omeprazole; Peptic Ulcer | 1998 |
[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
Safety profile of Lansoprazole: the US clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Esophageal Dis | 1999 |
[Proton pump inhibitors in pediatrics].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Child; Enzyme Inh | 1999 |
Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroi | 1999 |
[Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2000 |
Lansoprazole: an update of its place in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2001 |
Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2001 |
[Progress of tailor-made treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2002 |
Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis, | 2001 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2002 |
[The outline of medical treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Clari | 2002 |
[H. pylori eradication therapy and natural history of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enz | 2002 |
[Intractable ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differe | 2002 |
[Peptic ulcer in the elderly].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; | 2002 |
[Plaunotol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diterpenes; | 2002 |
[Ecabet sodium].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Animals; Anti-Ulcer Agents; Diterpe | 2002 |
[Polaprezinc].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Carnosine; Clarith | 2002 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
Proton-pump inhibition for acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Gast | 1991 |
88 trials available for lansoprazole and Peptic Ulcer
| Article | Year |
|---|---|
The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Esophagitis; Humans | 2022 |
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Topics: Adult; Esophagitis; Humans; Lansoprazole; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Sulfonamid | 2023 |
Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Esophagitis; Humans | 2023 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
[Is sequential eradication of Helicobacter pylori effective? Sequential treatment more effective than triple therapy in patients with clarithromycin resistance].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2013 |
Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Brazil; Disease Eradication; Double- | 2013 |
Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2013 |
Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers.
Topics: Adenocarcinoma; Aged; Alanine; Anti-Ulcer Agents; Dissection; Female; Gastroscopy; Humans; Iatrogeni | 2013 |
Stress ulcer prophylaxis in patients being weaned from the ventilator in a respiratory care center: A randomized control trial.
Topics: Aged; Aged, 80 and over; Female; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Peptic Ulcer | 2016 |
The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; DNA, Ribosomal; Drug Therapy, Combination; Femal | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug | 2016 |
Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2009 |
Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2010 |
Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Intravenous; Administration, Oral; Aged; An | 2012 |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 2002 |
Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2002 |
The effects of nocturnal acid breakthrough on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 2003 |
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2003 |
Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2004 |
Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 2004 |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Gastritis; | 2004 |
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth | 2004 |
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ben | 2004 |
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Anti-Ulcer Agents; Benz | 2005 |
Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2005 |
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2005 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2008 |
Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Base Sequence; Drug | 1995 |
Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Administration | 1995 |
13C-UBT using an infrared spectrometer for detection of Helicobacter pylori and for monitoring the effects of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Breath Tests; Carbon Dioxide; Carbon Iso | 1995 |
Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Jui | 1995 |
Quality of peptic ulcer healing induced by lansoprazole and roxatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal | 1995 |
Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Atrophy; Duodenal Ulcer; Gastric Mucosa; | 1995 |
Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Administration Schedule; Duo | 1995 |
The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibodi | 1995 |
Effect of lansoprazole on peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobacter Inf | 1995 |
Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Ulce | 1995 |
Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; | 1995 |
Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Biopsy; Endoscopy, Digestive Syst | 1995 |
An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 1993 |
Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithro | 1995 |
Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Amoxicillin; Anti-Ulcer Agents; Capsu | 1995 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1997 |
[Studies on the protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic acid. An endoscopic controlled double-blind study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Duo | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1997 |
Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Bacterial Protein | 1996 |
Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alanine; Amoxicillin; Anti-Infective Agents; A | 1998 |
Lansoprazole elevates the ratio of serum pepsinogen I v.s. pepsinogen II.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Helicobacter Infections; He | 1997 |
Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; | 1998 |
Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Cross-Over | 1998 |
[Eradication therapies for Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Factors influencing Helicobacter pylori eradication with 2 week combination therapy of lansoprazole and amoxycillin: intragastric distribution of colonization and gastric mucosal atrophy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Administration Sch | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; | 1998 |
[Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin | 1999 |
[A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Admini | 1999 |
[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1999 |
Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial | 1999 |
Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
Helicobacter treatment with quadruple therapy in primary health care for patients with a history of ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combinati | 1999 |
Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Re | 1999 |
Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 2000 |
Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2000 |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromy | 2000 |
Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antitrichomona | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles | 2000 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ul | 2001 |
A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2002 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
H2-receptor antagonist-refractory ulcer: its pathophysiology and treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dinoprostone; Female; Gastric Mucosa; Hi | 1991 |
54 other studies available for lansoprazole and Peptic Ulcer
| Article | Year |
|---|---|
Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).
Topics: Animals; Anti-Ulcer Agents; Dogs; Enzyme Inhibitors; Fumarates; Gastric Mucosa; H(+)-K(+)-Exchanging | 2012 |
Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cohort Studies; Cross-Sectional Studies; Drug Administration Sched | 2013 |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastri | 2013 |
What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Breath Tests; Case-Control Studies; Cla | 2013 |
Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Brazil; Breath Tests; Drug Admin | 2015 |
Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Body Mass Index; Body We | 2016 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2008 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Ster | 2011 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesop | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antigens, | 2004 |
CagA status and Helicobacter pylori eradication among dyspeptic patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2005 |
Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Dysp | 2007 |
Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Blood Chemical Analysis; Combined Modali | 1994 |
Suppression of Acid Secretion by Lansoprazole and its Effects on Helicobacter pylori. II. Poster presentations from the 2nd International Colloquium on Proton Pump Inhibitors. Houston, Texas, September 29, 1994.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Helicobacter | 1995 |
Clinical study on the pathophysiology and treatment of PPI-resistant ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Resistance; Duodenal Ulcer; Gastric | 1995 |
Factors affecting quality of ulcer healing after lansoprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Alcohol Drinking; Anti-Ulcer Agents; Duodenal | 1995 |
[Usefulness of every-other day administration of proton pump inhibitors from the standpoint of continuous 48-hour pH measurements-- Comparison of cimetidine, omeprazole, and lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cimetidine; Drug Administration Schedule | 1995 |
[Drug of the month. Lansoprazole (DakaR)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Humans; Lansoprazole; Omeprazole; Peptic | 1995 |
Treatment of acid peptic disease: focus on proton pump inhibitors. Proceedings of the 1st International Symposium on Lansoprazole. Athens, Greece, 24 September 1992.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Humans; Lansoprazole; Omeprazol | 1993 |
[What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Carcinogenicity Tests; Carcinoi | 1994 |
Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 1996 |
Only one proton-pump inhibitor for formulary.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Formularies as Topic; Humans; Lansoprazo | 1996 |
Eradication of Helicobacter pylori followed by reinfection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Blot | 1996 |
[Do other proton pump blockers have advantages over Antra (omeprazole)?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Humans; Lansoprazole; Om | 1996 |
[2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Humans; Lansoprazole; Om | 1996 |
Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Comb | 1997 |
Proton-pump inhibitors: three of a kind?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Human | 1997 |
[Lansoprazol: acid blocking in peptic disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Peptic | 1994 |
[Two step therapy for education of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 1997 |
Low dose, short-term, triple therapy for helicobacter pylori associated peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1997 |
Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Carcinoid Tumor; Famotidine; Hist | 1998 |
One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Clarithromycin; Drug Administ | 1998 |
Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Dru | 1998 |
[Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1998 |
Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1997 |
Treating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bism | 1998 |
Stress ulcer prevention and histamine-2-receptor antagonists: leaps of faith or back to the drawing board?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Histamine H2 Antagonists; Humans; Intens | 1999 |
Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Resistance, | 1999 |
Proton pump inhibitor therapy: preliminary results of a therapeutic interchange program.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Drug Costs; Humans; Lansopr | 2000 |
Current approaches to reducing gastrointestinal toxicity of low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2001 |
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Biological Transpo | 2001 |
Gastroprotective effect of aparisthman, a diterpene isolated from Aparisthmium cordatum, on experimental gastric ulcer models in rats and mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2001 |
Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Edema; Female; Hu | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
[The effectiveness of 7-day combined Helicobacter eradication therapy in patients with peptic ulcer and chronic gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chronic Disease | 2001 |
[Gastroduodenal ulcer in childhood].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Inflammatory Agents, Non-Ster | 2002 |
Failure of Helicobacter pylori eradication: is poor compliance the main cause?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2002 |
[Proton pump inhibitor for maintenance therapy of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Endoscopy, Gastrointestinal; H(+ | 1992 |
[Proton pump inhibitors in the treatment of peptic ulcers resistant to H2-receptor antagonists].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Depression, Chemical; Drug Resis | 1992 |
[Evaluation of the effect of proton pump inhibitors on stomal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Drug Evaluation; Endoscopy, Gast | 1992 |
[Proton-pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphate; Animals; Anti-Ulcer Agents; Energy | 1991 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esoph | 1991 |
Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Dogs | 1989 |